{"id":47943,"date":"2022-09-02T23:02:30","date_gmt":"2022-09-02T21:02:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/"},"modified":"2022-09-02T23:02:30","modified_gmt":"2022-09-02T21:02:30","slug":"nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/","title":{"rendered":"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing"},"content":{"rendered":"
\n

ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc<\/a><\/b><\/span>., <\/strong>(NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2022, the Company received notice from the Nasdaq Listing Qualifications Staff (the \u201cStaff\u201d) indicating that, based upon the Company\u2019s continued non-compliance with Nasdaq\u2019s minimum bid price requirement as of August 29, 2022, the Company securities would be subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the \u201cPanel\u201d). The Company plans to timely request a hearing, which request will stay any further action by the Staff at least pending the issuance of the Panel\u2019s decision following the hearing and the expiration of any extension that may be granted by the Panel.\n<\/p>\n

\nAbout NanoVibronix, Inc.<\/strong>\n<\/p>\n

\nNanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company\u2019s primary products include PainShield\u00ae and UroShield\u00ae, which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com<\/a>.\n<\/p>\n

\nForward-looking Statements<\/strong>\n<\/p>\n

\nThis press release contains \u201cforward-looking statements.\u201d Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company\u2019s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) the geographic, social and economic impact of COVID-19 on the Company\u2019s ability to conduct its business and raise capital in the future when needed, (ii) market acceptance of our existing and new products or lengthy product delays in key markets; (iii) negative or unreliable clinical trial results; (iv) inability to secure regulatory approvals for the sale of our products; (v) intense competition in the medical device industry from much larger, multinational companies; (vi) product liability claims; (vii) product malfunctions; (viii) our limited manufacturing capabilities and reliance on subcontractor assistance; (ix) insufficient or inadequate reimbursements by governmental and\/or other third party payers for our products; (x) our ability to successfully obtain and maintain intellectual property protection covering our products; (xi) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xii) our reliance on single suppliers for certain product components, (xiii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiv) our conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and\/or economic instabilities in specific jurisdictions; and (xv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the Securities and Exchange Commission (SEC), including the Company\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s web site at: http:\/\/www.sec.gov<\/a>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contacts:<\/strong>
Brett Maas, Managing Principal, Hayden IR, LLC
\n
brett@haydenir.com<\/a>
(646) 536-7331\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2022, the Company received notice from the Nasdaq Listing Qualifications Staff (the \u201cStaff\u201d) indicating that, based upon the Company\u2019s continued non-compliance with Nasdaq\u2019s minimum bid price … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47943","6":"format-standard","7":"category-industry"},"yoast_head":"\nNanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2022, the Company received notice from the Nasdaq Listing Qualifications Staff (the \u201cStaff\u201d) indicating that, based upon the Company\u2019s continued non-compliance with Nasdaq\u2019s minimum bid price ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-02T21:02:30+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing\",\"datePublished\":\"2022-09-02T21:02:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\\\/\"},\"wordCount\":704,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\\\/\",\"name\":\"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-09-02T21:02:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/","og_locale":"en_US","og_type":"article","og_title":"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing - Pharma Trend","og_description":"ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2022, the Company received notice from the Nasdaq Listing Qualifications Staff (the \u201cStaff\u201d) indicating that, based upon the Company\u2019s continued non-compliance with Nasdaq\u2019s minimum bid price ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-02T21:02:30+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing","datePublished":"2022-09-02T21:02:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/"},"wordCount":704,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/","url":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/","name":"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-09-02T21:02:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nanovibronix-announces-receipt-of-nasdaq-listing-determination-company-to-request-hearing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47943"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47943\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}